Sunnyvale, CA, United States
Sunnyvale, CA, United States

Time filter

Source Type

(San Diego, December 6, 2016) - A late-breaking abstract being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego shows patients who experience graft-versus-host disease (GVHD) after stem cell transplantation that is not resolved by corticosteroid treatment may benefit from the use of ibrutinib, an anti-cancer drug approved by the U.S. Food and Drug Administration for treating certain blood cancers. Sixty-seven percent of the trial's 42 participants who experienced GVHD responded to ibrutinib, and 71 percent showed sustained improvements with ibrutinib over a five-month period, results that are encouraging for a subset of patients with limited treatment options beyond corticosteroids, according to the researchers. "This is a very high response rate," said lead study author David Miklos, MD, of Stanford University. "These data are remarkable, and ibrutinib appears to exceed the therapeutic benefits of other agents. I think clinicians will find these data support the use of ibrutinib in patients with steroid refractory chronic GVHD (cGVHD), who currently suffer a range of symptoms that can be chronic and debilitating." Ibrutinib is designed to kill certain types of cancer cells by inhibiting the enzyme Bruton's tyrosine kinase (BTK). The new trial and pre-clinical laboratory studies suggest the drug's BTK inhibition activity and its inhibition of interleukin-2-inducible T-cell kinase (ITK) also make it a potent weapon against two types of immune cells -- T-cells and B-cells -- that are involved in GVHD. The researchers enrolled 42 patients who had undergone allogeneic stem cell transplantation, a procedure in which blood-forming stem cells are taken from a donor and injected into a patient to help replace blood cells that have been lost due to cancer or cancer treatments. About 10,000 people receive allogeneic stem cell transplants in the United States each year. Of these, about 4,000 subsequently experience GVHD, in which the transplanted stem cells attack the patient's body, causing symptoms such as rashes, mouth ulcers, dry eyes, gastrointestinal problems, shortness of breath, and decreased mobility in the joints and limbs. Immune-suppressing corticosteroid medications are the standard treatment for GVHD, but they do not benefit all patients. The patients in this trial showed sustained GVHD symptoms despite corticosteroid treatment. Five months after initiating treatment with ibrutinib, 71 percent experienced meaningful clinical improvements as indicated by decreases in clinician and patient assessments of symptom severity, a reduction in the number of organs affected, and analysis of biomarkers associated with GVHD. A substantial proportion of participants -- 45 percent -- experienced serious adverse events such as pneumonia, septic shock, or severe fever. Additional adverse events included fatigue, diarrhea, muscle spasms, nausea, and bruising. The researchers said these findings are in line with what had been reported in prior studies and underscore the importance of actively monitoring and managing any adverse events when prescribing ibrutinib. Overall, the researchers said ibrutinib represents a promising potential new therapy for GVHD. "By targeting allogeneic B-cells and TH2 lymphocytes, ibrutinib is targeting a pathogenic mechanism that we believe causes GVHD while leaving protective and anti-tumor cytotoxic T-cells intact," said Miklos. "This is a targeted therapy that does not just bluntly suppress the immune system; it leaves patients better able to fight their cancer as well as viral infections." The researchers and their collaborators are currently recruiting participants for several additional trials to further investigate the use of ibrutinib in preventing or treating GVHD and compare it to other agents. The study was funded by Pharmacyclics, LLC, an AbbVie Company, which makes ibrutinib. David Miklos, MD, Stanford University, Stanford, Calif., will present this study, titled "Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids,"(LBA-3) during the late-breaking abstracts session on Tuesday, December 6 at 7:30 a.m. PST in Hall AB. For the complete annual meeting program and abstracts, visit http://www. . Follow @ASH_hematology and #ASH16 on Twitter and like ASH on Facebook for the most up-to-date information about the 2016 ASH Annual Meeting. The American Society of Hematology (ASH) (http://www. ) is the world's largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 50 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. The Society publishes Blood (http://www. ), the most cited peer-reviewed publication in the field, as well as the newly launched, online, open-access journal, Blood Advances (http://www. ).


NEWARK, Calif., Dec. 08, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), today announced the appointment of Robert Booth, Ph.D. and Caroline Loewy to the company’s Board of Directors, effective December 6, 2016. "I am excited to welcome Dr. Robert Booth and Caroline Loewy to the CymaBay board. A major objective for us in 2016 has been to enrich our board of directors with experienced, respected, and highly accomplished drug development executives as we continue to advance our clinical programs. Robert and Caroline have significant strategic and operational experience in drug development and biotechnology,” said Harold Van Wart, Ph.D., Chief Executive Officer of CymaBay. “Robert is a veteran of the industry and a superb scientist with wide ranging expertise in many aspects of drug development. Caroline brings years of financial and operational experience with development stage biotechnology companies and a particular focus in supporting the advancement of therapies for rare diseases.” Dr. Robert Booth is the Founder and Chief Executive Officer of Virobay, Inc., a drug discovery and development company. He served concurrently as an Operating Partner and Senior Advisor at TPG Biotech. Dr. Booth is also the Executive Chairman and co-founder of Ab Initio Biotherapeutics and of CuraSen Therapeutics. Dr. Booth was appointed to the position of Consulting Professor in the School of Medicine at Stanford University in 2016. From 2002 to 2006, Dr. Booth was the Chief Scientific Officer at Celera Genomics, where he was responsible for leading all discovery and development activities. Dr. Booth conceived and initiated the Btk tyrosine kinase inhibitor program that was licensed to Pharmacyclics and from which Imbruvica was discovered and developed. Dr. Booth served on the board of directors of Pharmacyclics until its acquisition by Abbvie for $21 billion in 2015. Dr. Booth was at Roche from 1989 to 2002, in positions of increasing responsibility and was the Senior Vice President and Business Unit Leader for Roche in Palo Alto, California. Dr. Booth was a member of the Global Research Management Team and a member of the Business Development Committee, which oversaw licensing opportunities for Roche. The biology team for which Dr. Booth was responsible discovered and contributed to the development of Invirase, the first HIV protease inhibitor to be launched. Dr. Booth currently serves as a member of the board of directors of Glialogix, Inc., CuraSen Therapeutics and Ab Initio Biotherapeutics and Virobay, Inc. He has approximately 50 published scientific articles and is an inventor on 9 patents. Caroline Loewy is a biopharmaceutical and financial executive with over 25 years of experience in the field. She is a Co-Founder and the Chief Business Officer and Chief Financial Officer of Achieve Life Sciences, as well as a consultant providing strategic advisory services for biopharmaceutical companies. Caroline has previously held the position of Chief Financial Officer of both public and private biopharmaceutical companies Tobira Therapeutics, Corcept Therapeutics, and Poniard Pharmaceuticals. Prior to her roles in company management, Caroline spent 11 years as a senior biotechnology equity research analyst at Morgan Stanley and Prudential Securities. Caroline has leveraged her experience in the medical arena and financial expertise to benefit those affected by rare disease. She is a founding board member of the Global Genes Project, one of the leading rare disease patient advocacy organizations in the world, and is a member of the National Advisory Council of the Translational Genomics Research Institute (TGen) Center for Rare Childhood Disorders. Caroline is also a founding board member of the KCNQ2 Cure Alliance, promoting education and research into the rare disorder affecting her son. CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat diseases with high unmet medical need, including serious rare and orphan disorders. Seladelpar is a potent, selective, orally active PPARδ agonist. CymaBay has recently completed a Phase 2 study of seladelpar in patients with primary biliary cholangitis as well as a pilot Phase 2 study in patients with homozygous familial hypercholesterolemia, establishing proof-of-concept in both indications. Previously, a Phase 2 study of seladelpar in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. Arhalofenate, CymaBay’s other product candidate, is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in gout patients. Arhalofenate has been found to reduce painful flares in joints while at the same time promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia.


News Article | November 14, 2016
Site: globenewswire.com

LEXINGTON, Mass., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced the appointment of Lori A. Kunkel, M.D. to its Board of Directors. Dr. Kunkel currently serves on the Board of Directors at Loxo Oncology, where she was formerly Acting Chief Medical Officer.  Prior to Loxo Oncology, Dr. Kunkel served as Chief Medical Officer at Pharmacyclics, Inc. leading integrated clinical development highlighted by the approval of IMBRUVICA®. She has also served as Chief Medical Officer at Proteolix Inc. (acquired by Onyx), Syndax, and ACT Biotech. Prior to joining the biotechnology industry in 1995, Dr. Kunkel spent ten years in academic/clinical medicine and served as a faculty member in the Division of Hematology/Oncology’s Bone Marrow Transplant Unit at University of California, Los Angeles. She trained in internal medicine at Baylor College of Medicine, hematology at USC and oncology at UCLA, earning board certifications in these specialties. “We are delighted to welcome Lori to the Board of Curis and we will benefit tremendously from her depth of experience and instincts as we develop our drug candidates and place the company on a path for approval and commercialization of our products,” said CEO Ali Fattaey.  “Lori is well known and respected in the biotechnology community and we have benefited from her role as an advisor to the company in the past.” “I am pleased to join the Curis Board and look forward to working closely with the Board and management team as we collectively advance Curis as a leading oncology company,” said Dr. Kunkel. About Curis, Inc.  Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers. The Company's clinical drug candidates include CUDC-907, which is being investigated in a Phase 2 trial in patients with Diffuse Large B Cell Lymphoma, or DLBCL, and in a separate Phase 1 trial in patients with solid tumors. As part of a broad collaboration with Aurigene, Curis has an exclusive license to CA-170, an oral small molecule PD-L1/VISTA antagonist that is currently being investigated in a Phase 1 trial in patients with solid tumors or lymphoma. Curis also has an exclusive license to oral small molecule antagonists of the PD-1 and TIM-3 pathways, including PD-L1/TIM-3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948.  Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis's website at www.curis.com. Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the potential advantages and benefits of small molecule checkpoint inhibitors and the Company's plans and expectations for the collaboration with Aurigene, including its plans to discover and develop multiple first-in-class oral, small molecule checkpoint inhibitors for the treatment of patients with cancer. Forward-looking statements may contain the words "believes," "expects," "anticipates," "plans," "seeks," "estimates," "assumes," "will," "may," "could" or similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other important factors that may cause actual results to be materially different from those indicated by such forward-looking statements. For example, Curis may experience adverse results, delays and/or failures in its drug development programs and may not be able to successfully advance the development of its drug candidates in the time frames it projects, if at all. Curis's drug candidates may cause unexpected toxicities, fail to demonstrate sufficient safety and efficacy in clinical studies and/or may never achieve the requisite regulatory approvals needed for commercialization. Favorable results seen in preclinical studies and early clinical trials of Curis's drug candidates may not be replicated in later trials. There can be no guarantee that the collaboration agreement with Aurigene will continue for its full term, that Curis or Aurigene will each maintain the financial and other resources necessary to continue financing its portion of the research, development and commercialization costs, or that the parties will successfully discover, develop or commercialize drug candidates under the collaboration. Regulatory authorities may determine to delay or restrict Genentech's and/or Roche's ability to continue to develop or commercialize Erivedge in BCC. Erivedge may not demonstrate sufficient or any activity to merit its further development in disease indications other than BCC. Competing drugs may be developed that are superior to Erivedge. Curis faces risks relating to its wholly-owned subsidiary's royalty-collateralized loan transaction, including the risk that it may not receive sufficient levels of royalty revenue from sales of Erivedge to satisfy the debt obligation or may otherwise lose its rights to royalties and royalty-related payments as a result of a foreclosure of the loan. Curis will require substantial additional capital to fund its business and such capital may not be available on reasonable terms, or at all. Curis faces substantial competition. Curis also faces risks relating to potential adverse decisions made by the FDA and other regulatory authorities, investigational review boards, and publication review bodies. Curis may not obtain or maintain necessary patent protection and could become involved in expensive and time-consuming patent litigation and interference proceedings. Unstable market and economic conditions and unplanned expenses may adversely affect Curis's financial conditions and its ability to access the substantial additional capital needed to fund the growth of its business. Important factors that may cause or contribute to such differences include the factors set forth under the caption “Risk Factors” in our in our most recent Form 10-K and Form 10-Q and the factors that are discussed in other filings that we periodically make with the Securities and Exchange Commission (“SEC”). In addition, any forward-looking statements represent the views of Curis only as of today and should not be relied upon as representing Curis's views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by law.


BEERSE, Belgio--(BUSINESS WIRE)--Janssen-Cilag International NV ha annunciato in data odierna i risultati di follow-up più estesi ad oggi relativi a pazienti affetti da leucemia linfatica cronica (LLC) trattati con Imbruvica®▼ (ibrutinib), dimostrando risposte elevate e durature per cinque anni.1 Questi dati aggiornati di fase 1b/2 hanno dimostrato un tasso di risposta complessiva (Overall Response Rate, ORR) dell’89%2 compresi pazienti con mutazioni genetiche associate a scarsi risultati. Una risposta completa (Complete Response, CR) è stata osservata nel 29% dei pazienti trattati nell’ambito della prima linea.2 La sopravvivenza libera da progressione (Progression-Free Survival, PFS) è migliorata avviando prima la terapia in pazienti non trattati in precedenza (Treatment Naïve, TN) e in pazienti recidivanti/refrattari (r/r).2 Questi dati (abstract #2331) sono stati illustrati sabato 3 dicembre con una presentazione orale2 nell'ambito del 58th Annual American Society of Hematology (ASH) Meeting and Exposition svoltosi a San Diego, CA. “Questi risultati a lungo termine hanno dimostrato che ibrutinib può aiutare i pazienti a mantenere la leucemia linfatica cronica in remissione completa o parziale per un periodo esteso di tempo, fino a cinque anni, senza chemioterapia”, ha spiegato Susan O’Brien, M.D., Associate Director for Clinical Science, Chao Family Comprehensive Cancer Center presso UC Irvine Health, Medical Director, Sue and Ralph Stern Center for Clinical Trials & Research, nonché ricercatrice e presentatrice degli studi clinici PCYC-1102 e PCYC-1103.* “Questi dati indicano inoltre che il periodo libero da progressione della malattia è più esteso per i pazienti quando il trattamento con ibrutinib viene avviato prima possibile nel corso della malattia.” Abstract #233: Five-Year Experience With Single-Agent Ibrutinib In Patients With Previously Untreated And Relapsed/Refractory Chronic Lymphocytic Leukaemia (Esperienza di cinque anni con ibrutinib in monoterapia in pazienti con leucemia linfatica cronica recidivata/refrattaria non trattati in precedenza)1,2 In questi studi (PCYC-1102 e PCYC-1103), con cinque anni di follow-up, l'ORR nei pazienti trattati con ibrutinib è stato dell'89%,2 con 14% dei pazienti che ottenevano risposte complete (CR)2 [ORR dell'87% con 29% di CR in pazienti TN (n=31) e ORR dell'89% ORR con 10% di CR in pazienti r/r (n=101)].2 La durata mediana dello studio è stata di 62 mesi (1-67) per i pazienti TN2 e 49 mesi (1-67) per i pazienti r/r.2 La sopravvivenza complessiva (Overall Survival, OS) a cinque anni è stata pari al 92% per i pazienti TN e al 57% per i pazienti r/r, con un tasso PFS rispettivamente del 92% e del 43%.2 L’OS mediana e la durata mediana della risposta (Duration of Response, DOR) non sono state raggiunte. La PFS mediana non è stata raggiunta nei pazienti TN ed è stata di 52 mesi per i pazienti r/r.2 I risultati sono stati coerenti nei pazienti r/r con LLC ad alto rischio e fattori di rischio tradizionalmente associati a risultati scarsi4 compresi quelli con delezione 11q (del 11q; n=28), delezione 13q (del 13q; n=13), delezione 17p (del 17p; n=34) e regione variabile delle catene pesanti delle immunoglobuline (IGHV) immutata (n=79).2 La PFS mediana era di 55 mesi (31-NE) per i pazienti con del 11q, 26 mesi (95% CI, 18-37) per i pazienti con del 17p, 43 mesi (95% CI, 32-non calcolabile) per i pazienti con IGHV immutato, e non è stata raggiunta per i pazienti con del 13q.2 I risultati hanno indicato che PFS e OS erano maggiori quando la terapia con ibrutinib veniva avviata prima.2 La PFS mediana non è stata raggiunta nei pazienti TN2 ed è stata di 63 mesi per i pazienti r/r che avevano già ricevuto uno o 2 regimi,2 59 mesi per i pazienti che avevano già ricevuto tre regimi,2 e 39 mesi per quanti avevano già ricevuto quattro o più regimi.2 “L’evidenza definitiva a supporto dei benefici di ibrutinib per i paizenti continua a crescere, e questi dati provenienti da un periodo più esteso di cinque anni di trattamento della LLC offrono importanti rassicurazioni sull’effetto duraturo ottenibile con ibrutinib nel tempo”, ha dichiarato Jane Griffiths, presidente del gruppo Janssen per l’Europa, Medio Oriente e Africa. “Siamo così entusiasti di cambiare lo scenario terapeutico e il significato della diagnosi per i pazienti con LLC, grazie a questi miglioramenti clinicamente significativi”. Lo studio clinico di Fase 1b/2 PCYC-1102 ha valutato la sicurezza e l’efficacia della monoterapia a base di ibrutinib in 132 pazienti affetti da LLC: 31 pazienti erano TN: 101 erano r/r.2 I pazienti hanno ricevuto 420 mg o 840 mg una volta al giorno fino alla progressione della malattia o tossicità inaccettabile.2 Fra i pazienti r/r, 34% avevano del 17p, 35% del 11q, 47% avevano del 13q e 78% IGHV immutato.2 L’endpoint primario era la ORR, con endpoint secondari DOR e PFS oltre alla sicurezza. PCYC-1103 è lo studio di estensione a lungo termine. I risultati primari di questo studio clinico sono stati pubblicati in The New England Journal of Medicine nel giugno 20135 e hanno costituito la base dell’approvazione iniziale di ibrutinib per il trattamento della LLC negli Stati Uniti nel febbraio 2014 mediante la designazione di breakthrough therapy (farmaco fortemente innovativo).6 Abstract #234: Updated Efficacy and Safety From The Phase 3 RESONATE-2 Study: Ibrutinib as First-Line Treatment Option in Patients 65 Years and Older With Chronic Lymphocytic Leukaemia (Dati aggiornati di efficacia e sicurezza dallo studio clinico di Fase III RESONATE-2: ibrutinib come opzione terapeutica di prima linea in pazienti di almeno 65 anni di età affetti da leucemia linfatica cronica)3 I risultati aggiornati dello studio pivotale di fase III RESONATE-2 (PCYC-1115) hanno dimostrato che a un follow-up mediano di 29 mesi, ibrutinib ha continato ad avere notevole efficacia come terapia di prima linea nella LLC. Secondo i risultati dello studio, ibrutinib ha ridotto il rischio di progressione o morte dell’88% rispetto a clorambucile, l’agente chemioterapico comunemente impiegato. A 24 mesi, il tasso di PFS era dell'89% per i pazienti trattati con ibrutinib e del 34% per il braccio trattato con clorambucile [HR, 0,121; 95% CI 0,074-0,198; p<0,0001). L’ORR valutato dai ricercatori con questo follow-up più esteso era del 92% con ibrutinib e del 36% con clorambucile; nel braccio trattato con ibrutinib, la CR o CR con recupero incompleto del midollo osseo (Cri) migliorava dal 15% a 24 mesi al 18% con un follow-up più esteso di 29 mesi. RESONATE-2 è uno studio clinico randomizzato, in aperto, multicentrico di fase III in corso sponsorizzato da Pharmacyclics, condotto fra 269 pazienti affetti da LLC di almeno 65 anni di età, non trattati in precedenza, nell'UE, negli Stati Uniti e in altre regioni del mondo. I pazienti sono stati randomizzati per ricevere un dose orale giornaliera di ibrutinib 420 mg fino a progressione della malattia o tossicità inaccettabile, oppure clorambucile nei giorni 1 e 15 di ogni ciclo di 28 giorni, fino a un massimo di 12 cicli. La dose iniziale per clorambucile nel Ciclo 1 era di 0,5 mg/kg, incrementata sulla base della tollerabilità nel Ciclo 2 per incrementi di 0,1 mg/kg fino a un massimo di 0,8 mg/kg. Lo studio ha incontrato il suo endpoint primario, dimostrando un miglioramento della PFS, valutata da un comitato di revisione indipendente (IRC). I risultati iniziali di RESONATE-2 erano stati presentati in una sessione orale al meeting dell'American Society of Hematology (ASH) nel dicembre 20158 e pubblicati simultaneamente su The New England Journal of Medicine.7 Le società del gruppo Janssen Pharmaceutical Companies di Johnson & Johnson sono impegnate a eliminare le malattie dal mondo: trasformare la vita con nuovi e migliorati metodi per prevenire, intercettare, trattare e curare le malattie è la nostra fonte di ispirazione. Riuniamo le menti migliori e scegliamo i percorsi scientifici più promettenti. Siamo il marchio Janssen. Collaboriamo a livello internazionale per la salute di tutti, in tutto il mondo. Per ulteriori informazioni visitare il sito www.janssen.com. Per le notizie più aggiornate seguiteci su www.twitter.com/janssenEMEA. Il presente comunicato stampa contiene "dichiarazioni a carattere previsionale" secondo la definizione del Private Securities Litigation Reform Act del 1995 relativa allo sviluppo di un prodotto. Si avvisano i lettori di non fare affidamento su tali dichiarazioni a carattere previsionale, che si basano sulle aspettative correnti per eventi futuri. Nel caso in cui le ipotesi di base dovessero rivelarsi imprecise, o si dovessero concretizzare rischi noti o sconosciuti o incertezze, i risultati effettivi potrebbero presentare differenze materiali con le aspettative e le previsioni di Janssen-Cilag International NV e/o di Johnson & Johnson. Rischi e incertezze includono, ma non a titolo esaustivo: difficoltà e incertezze nello sviluppo del prodotto, compresa l'incertezza del successo clinico e dell’ottenimento delle autorizzazioni previste dalla legge; incertezza del successo commerciale di nuovi prodotti o nuove indicazioni; la concorrenza, compresi progressi tecnologici, nuovi prodotti e brevetti ottenuti dai concorrenti; difficoltà relative ai brevetti; cambiamenti nelle leggi e normative, comprese riforme globali nell'assistenza sanitaria; e la tendenza al contenimento dei costi in ambito di assistenza sanitaria. Un ulteriore elenco con la descrizione di questi rischi, incertezze e altri fattori è riportato nella relazione annuale di Johnson & Johnson sul modello Form 10-K relativa all’esercizio terminato il 3 gennaio 2016, nell’Exhibit 99 accluso, e nei documenti successivamente depositati dall’azienda presso la Securities and Exchange Commission. Copie di questi documenti sono disponibili online all’indirizzo www.sec.gov, www.jnj.com oppure possono essere richieste a Johnson & Johnson. Nessuna delle società di Janssen Pharmaceutical Companies o di Johnson & Johnson si impegna ad aggiornare tali dichiarazioni a carattere previsionale a seguito di nuove informazioni o di eventi o sviluppi futuri. 1. O’Brien S, Furman R, Coutre S, et al. Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia. Presentazione orale al 58th Annual Meeting and Exposition of the American Society of Hematology, San Diego, USA, 3-6 dicembre 2016: Abstract #233. Presentato il 3 dicembre 2016. Disponibile su: https://ash.confex.com/ash/2016/webprogram/Paper89757.html. Ultimo accesso novembre 2016. 2. O’Brien S, Furman R, Coutre S, et al. Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia. Presentazione orale al 58th Annual Meeting and Exposition of the American Society of Hematology, San Diego, USA, 3-6 dicembre 2016. Presentato il 3 dicembre 2016. 3. Barr P, Robak T, Owen C, et al. Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia. Presentazione orale al 58th Annual Meeting and Exposition of the American Society of Hematology, San Diego, USA, 3-6 dicembre 2016: Abstract #234. Disponibile su: https://ash.confex.com/ash/2016/webprogram/Paper89615.html. Ultimo accesso novembre 2016. 5. Byrd J, Furman R, Coutre S, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32-42. 6. Johnson & Johnson. IMBRUVICA™ (ibrutinib) Now Approved in the U.S. for Patients with Chronic Lymphocytic Leukemia Who Have Received At Least One Prior Therapy. Comunicato stampa, 12 febbraio, 2014. Disponibile su: http://www.investor.jnj.com/releasedetail.cfm?releaseid=825570. Ultimo accesso novembre 2016. 7. Burger J, Tedeschi A, Barr P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015:373:2435-37. 8. Janssen. Ibrutinib (IMBRUVICA®) Significantly Improved Progression-Free and Overall Survival Versus Chlorambucil in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia. Comunicato stampa, 6 dicembre 2015. Disponibile su: http://www.janssen.com/ibrutinib-imbruvica-significantly-improved-progression-free-and-overall-survival-versus-chlorambucil. Ultimo accesso novembre 2016. 9. O’Brien S, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15:48-58.


CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genentech and Bristol-Myers Squibb (BMS) lead oncology franchises in image and engagement according to oncologists, who give them top scores across multiple metrics. Merck, Novartis, Amgen and Celgene rank in the second tier, with eight additional companies rounding out the field. In specific tumor areas, Genentech is the frontrunner in breast cancer, colorectal cancer and chronic lymphocytic leukemia. BMS is perceived as the leader in melanoma and lung cancer, and Celgene leads in multiple myeloma. Across several tumor areas, checkpoint inhibitors such as PD-1 and PD-L1 emerge as game changers in 2016 and over the next five years in the minds of physicians. These and other findings (including hematologist perceptions) are from Pharma Engage® a Cogent Reports study released by Market Strategies International. “It’s critical for pharmaceutical companies to engage with physicians across a variety of settings to foster strong relationships, yet motivating physicians to engage is not always easy,” said Caroline Brennan, Ph.D., vice president of the Life Sciences division at Market Strategies. “We found that likelihood to engage with a manufacturer is strongly linked to image, so firms can increase physician engagement by improving their image.” According to Brennan, “having a relevant product portfolio is the number one driver of image. However, that does not mean the smaller firms are out of luck. It simply means they need to focus on other attributes that will improve their image, such as innovative R&D and HCP educational resources. Each company has its own set of priority levers, and companies that don’t invest in them will have a tougher time establishing meaningful engagement.” “It’s particularly important to note that the companies being noticed for making great strides in immunotherapy and other novel mechanisms of action are also the ones rising to the top in image within specific tumor types,” she added. “It will be interesting to see how future discoveries impact image moving forward.” Cogent Reports conducted an online study among 157 office-based oncologists and 103 hematologists who were recruited from a national online panel in November 2016. To qualify, physicians needed to be board-certified and were required to have a minimum number of oncology patients, spend at least 50%–60% of their time in patient care and have exposure to sales representatives. This study evaluates and ranks Amgen, Astellas, AstraZeneca, Bayer, BMS, Celgene, Genentech, J&J/Janssen, Lilly, Merck & Co, Novartis, Otsuka, Pfizer and Takeda on: The study also examines leadership across six key tumor areas: breast, lung, colorectal, melanoma, CLL and multiple myeloma. Companies vary by tumor type and include a relevant subset of the companies above as well as AbbVie, Gilead, Incyte, Medivation, Pharmacyclics, Prometheus, Sanofi and Teva, where applicable. Market Strategies International is a market research consultancy with deep expertise in health, consumer & retail, energy, financial services, technology and telecommunications. We blend primary research with data from our syndicated, benchmarking and self-funded studies as well as Big Data to provide clients with the most complete and accurate insights needed to make confident business decisions. Market Strategies’ research specialties include brand, communications, CX, product development and segmentation. Our syndicated products, known as Cogent Reports, help clients understand the market environment, explore industry trends and monitor their brand and products within the competitive landscape. Founded in 1989, Market Strategies is one of the largest market research firms in the world, with offices in the US, Canada and China. Read Market Strategies’ blog at FreshMR, and follow us on Facebook, Twitter and LinkedIn.


BEERSE, Belgique--(BUSINESS WIRE)--Janssen-Cilag International NV a annoncé les résultats du plus long suivi réalisé à ce jour pour des patients suivant un traitement à l'Imbruvica®▼ (ibrutinib) contre la leucémie lymphoïde chronique (LLC), faisant état de réponses élevées et durables sur cinq ans.1 Ces données mises à jour de Phase 1b/2 ont montré un taux de réponse globale (TRG) de 89%,2 y compris les patients avec des mutations génétiques associées à des pronostics médiocres. Une réponse complète (RC) a été observée chez 29% des patients traités en première ligne.2 La survie sans progression de la maladie (SSPM) s'est améliorée en lançant plus tôt le traitement chez les patients naïfs de traitement (NT) et les patients en rechute ou réfractaires (r/r).2 Ces données (résumé #2331) ont été présentées samedi 3 décembre lors d'une présentation orale2 prononcée à la 58e conférence et exposition annuelles de l'American Society of Hematology (ASH) à San Diego, en Californie. Les données du suivi chez les patients atteints de LLC et traités à l'ibrutinib pendant 29 mois à partir de la Phase 3 de l'essai RESONATE-2 ont également été présentées samedi (résumé #2343). L'ibrutinib, inhibiteur de premier ordre de la tyrosine kinase de Bruton (BTK), est développé conjointement par Cilag GmbH International (une filiale de Janssen) et Pharmacyclics/AbbVie. Les filiales de Janssen commercialisent l’ibrutinib dans la région EMOA (Europe, Moyen-Orient et Afrique) ainsi que dans le reste du monde, à l’exception des États-Unis, où les deux sociétés assurent une commercialisation conjointe. « Ces résultats à plus long terme démontrent que l'ibrutinib peut aider les patients atteints de leucémie lymphoïde chronique à rester dans un état de rémission complète ou partielle sur une longue période de cinq années, sans chimiothérapie », déclare Susan O’Brien, DG, directrice adjointe des Sciences cliniques, au Chao Family Comprehensive Cancer Center de l'UC Irvine Health, directrice médicale, au Sue and Ralph Stern Center for Clinical Trials & Research, et chercheur et présentatrice des essais PCYC-1102 et PCYC-1103.* « De plus, ces données indiquent que la durée sans progression de la maladie est plus longue lorsque le traitement à l'ibrutinib est démarré le plus tôt possible. » Dans ces études (PCYC-1102 et PCYC-1103), avec cinq années de suivi, le TRG chez les patients traités à l'ibrutinib était de 89%,2 avec 14% des patients atteignant une réponse complète (RC)2 [TRG de 87% avec 29% de RC chez les patients NT (n=31) et TRG de 89% avec 10% de RC chez les patients r/r (n=101)].2 La durée médiane d'étude était de 62 mois (1-67) pour les patients NT2 et de 49 mois (1-67) pour les patients r/r.2 La survie globale (SG) à cinq ans était de 92% pour les patients NT et de 57% pour les patients r/r, avec un taux respectif de SSPM de 92% et 43%.2 La SG médiane et la durée de réponse médiane n'ont pas été atteintes. La SSPM médiane n'a pas été atteinte pour les patients NT, et était de 52 mois pour les patients r/r.2 Les résultats étaient cohérents chez les patients r/r atteints de LLC à risque élevé, et les facteurs de risques ont traditionnellement été associés à des pronostics médiocres4 y compris pour ceux avec délétion 11q (del11q; n=28), délétion 13q (del13q; n=13), délétion 17p (del17p; n=34) et une région variable de chaîne lourde d'immunoglobuline non mutée (IGHV; n=79).2 La SSPM médiane était de 55 mois (31-NE) pour ceux avec del11q, 26 mois (95% CI, 18-37) pour ceux avec del17p, 43 mois (95% CI, 32-non estimable) pour ceux avec une IGHV non mutée, et n'a pas était atteinte pour ceux avec del13q.2 Les résultats ont indiqué que la SSPM et la SG étaient supérieures lorsque le traitement à l'ibrutinib démarré plus tôt.2 La SSPM médiane n'a pas été atteinte chez les patients NT2 et était de 63 mois pour les patients r/r qui avaient déjà reçu un ou deux régimes médicamenteux,2 de 59 mois pour ceux qui avaient déjà reçu trois régimes,2 et de 39 mois pour ceux qui avaient déjà reçu quatre régimes ou plus.2 « Les preuves irréfutables en faveur des avantages de l'ibrutinib pour les patients continuent d'arriver, et ces données à plus long terme, pendant cinq années de traitement anti LLC, sont une importante confirmation des effets durables qui peuvent être obtenus avec l'ibrutinib », souligne Jane Griffiths, présidente du groupe Janssen Europe, Moyen-Orient et Afrique. « Grâce à ces améliorations cliniques significatives, nous sommes heureux de modifier l'horizon thérapeutique et les diagnostics pour les patients atteints de LLC. » Aucun nouveau signal d'innocuité n'a été constaté durant l'étude.2 L'apparition d'effets indésirables en cours de traitement de niveau trois ou supérieur, pour tous les patients, était plus élevée au cours de la première année et a diminué avec le temps. Les effets indésirables les plus fréquents ont été l'hypertension (26%), la pneumonie (22%), la neutropénie (17%) et la fibrillation auriculaire (9%).2 La Phase 1b/2 de l'essai PCYC-1102 a évalué l'innocuité et l'efficacité de l'ibrutinib en monothérapie chez 132 patients atteints de LLC: 31 patients étaient NT: 101 étaient r/r.2 Les patients ont reçu 420 mg ou 840 mg une fois par jour jusqu'à progression de la maladie ou jusqu'à un niveau de toxicité inacceptable.2 Parmi les patients r/r, 34% étaient del17p, 35% del11q, 47% del13q et 78% IGHV non mutée.2 Le critère principal était le TRG, et les critères secondaires étaient la durée de réponse et la SSPM, en plus de l'innocuité. La PCYC-1103 est l'étude d'extension longue durée. Les résultats primaires de cet essai avaient été publiés dans The New England Journal of Medicine en juin 20135 et ont servi de base à l'approbation initiale de l'ibrutinib aux États-Unis pour les patients atteints de LLC en février 2014 avec l'obtention de la Breakthrough Therapy Designation.6 Résumé #234: Efficacité et innocuité mises à jour pour la Phase 3 de l'étude RESONATE-2: l'ibrutinib en tant qu'option thérapeutique de première ligne pour les patients âgés de 65 ans et plus atteints de leucémie lymphoïde chronique3 Les résultats mis à jour de l'étude pivot RESONATE-2 de Phase 3 (PCYC-1115) ont démontré qu'à une moyenne de 29 mois de suivi, l'ibrutinib continuait d'avoir une efficacité substantielle en tant que thérapie de première ligne contre la LLC. Selon l'étude, l'ibrutinib a réduit de 88% le risque de progression ou de décès en comparaison avec le chlorambucil, un agent de chimiothérapie communément utilisé. À 24 mois, la SSPM était de 89% pour les patients prenant de l'ibrutinib et de 34% pour le chlorambucil [HR, 0,121; 95% CI 0,074-0,198; p<0,0001). Le TRG évalué par les chercheurs pendant ce suivi de plus longue durée était de 92% avec l'ibrutinib et de 36% avec le chlorambucil ; avec l'ibrutinib, les RC ou RC avec rétablissement médullaire incomplet ont connu une amélioration, passant de 15% à 24 mois, à 18% avec un suivi de 29 mois. Les résultats d'innocuité étaient conformes avec l'analyse primaire de l'étude, et ont démontré que les effets indésirables de niveau 3 ou supérieur ont diminué avec le temps. La plupart des effets indésirables qui ont conduit à un abandon thérapeutique se sont produits durant la première année de traitement. Les effets indésirables de niveau ≥ 3 les plus fréquents (≥5%) étaient la neutropénie (12%), la pneumonie (7%), l'anémie (7%) et l'hypertension (5%). RESONATE-2 est une étude en cours de Phase 3, sponsorisée par Pharmacyclics, randomisée, multicentrique et ouverte, réalisée auprès de 269 patients naïfs de traitement et atteints de LLC, âgés de 65 ans et plus, dans l'UE, aux États-Unis et dans d'autres régions. Les patients ont été randomisés pour recevoir de l'ibrutinib 420 mg par voie orale, une fois par jour jusqu'à progression ou toxicité inacceptable, ou du chlorambucil les jours 1 et 15 de chaque cycle de 28 jours et jusqu'à 12 cycles. La dose de départ de chlorambucil pendant le Cycle 1 était de 0,5 mg/kg et a été augmentée en fonction de la tolérabilité pendant le Cycle 2 par paliers de 0,1 mg/kg jusqu'à un maximum de 0,8 mg/kg. L'étude a validé son critère principal en démontrant une amélioration de la SSPM, telle qu'évaluée par un comité d'évaluation indépendant. Les résultats initiaux de RESONATE-2 avaient été présentés au cours d'une session orale à la conférence de l'American Society of Hematology (ASH) en décembre 20158 et publiés simultanément dans The New England Journal of Medicine.7 La LLC est une maladie chronique ; la durée de survie globale médiane varie entre 18 mois et plus de 10 ans en fonction du stade de la maladie.12 La maladie évolue finalement chez la majorité des patients, et les patients ont à chaque fois un nombre plus réduit d’options de traitement. On prescrit souvent aux patients de multiples lignes de traitement lorsqu’ils rechutent ou deviennent résistants aux traitements. Dans les sociétés pharmaceutiques Janssen du groupe Johnson & Johnson, nous œuvrons à créer un monde sans maladie. Transformer les vies en trouvant des moyens nouveaux et meilleurs pour prévenir, intercepter, traiter et guérir les maladies est pour nous une source d'inspiration. Nous réunissons les plus brillants esprits et recherchons la science la plus prometteuse. Nous sommes Janssen. Nous collaborons dans le monde entier au service de la santé de tous. Pour en savoir plus, rendez-vous sur www.janssen.com. Suivez-nous sur www.twitter.com/janssenEMEA pour connaître toute notre actualité. Le présent communiqué de presse contient des « énoncés prospectifs » au sens de la loi Private Securities Litigation Reform Act de 1995 pour ce qui concerne le développement de produits. Il est conseillé au lecteur de ne pas placer une confiance excessive dans ces énoncés prospectifs. Ces énoncés sont fondés sur les attentes actuelles par rapport à des événements futurs. Si les suppositions sous-jacentes s’avèrent inexactes ou si des risques ou incertitudes, connus ou inconnus, se matérialisent, les résultats réels pourraient différer sensiblement des attentes et projections de Janssen-Cilag International NV et/ou de Johnson & Johnson. Les risques et incertitudes incluent, sans toutefois s’y limiter : les défis et incertitudes inhérents au développement de produits, y compris l’incertitude quant à la réussite clinique et à l’obtention des autorisations réglementaires ; l’incertitude quant au succès commercial ; la concurrence, y compris les progrès technologiques, les nouveaux produits et brevets obtenus par nos concurrents ; les difficultés ou retards dans la fabrication ; la contestation de brevets ; les préoccupations concernant l’efficacité ou l’innocuité de produits résultant de rappels de produits ou d’actions réglementaires ; les modifications des comportements et des habitudes d’achat ou les difficultés financières des acheteurs de produits et de services de soins de santé ; ainsi que les tendances envers la maîtrise des coûts des soins de santé. Une liste et une description plus exhaustives de ces risques, incertitudes et autres facteurs figurent dans le rapport annuel de Johnson & Johnson sur formulaire 10-K pour l’exercice clos au 3 janvier 2016, notamment dans la partie 99 de celui-ci, et dans les documents déposés ultérieurement par la société auprès de la Commission américaine des opérations de Bourse (la « SEC »). Des exemplaires de ces documents sont disponibles en ligne sur www.sec.gov, www.jnj.com ou sur demande auprès de Johnson & Johnson. Aucune des sociétés pharmaceutiques Janssen, ni Johnson & Johnson n’assume l’obligation de mettre à jour un quelconque énoncé prospectif suite à de nouvelles informations ou à des événements ou développements futurs. 1. O’Brien S, Furman R, Coutre S, et al. Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia. Oral presentation at the 58th Annual Meeting and Exposition of the American Society of Hematology, San Diego, USA, 3-6 December 2016: Abstract #233. Presented on 3 December 2016. Disponible sur: https://ash.confex.com/ash/2016/webprogram/Paper89757.html. Dernière consultation novembre 2016. 2. O’Brien S, Furman R, Coutre S, et al. Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia. Oral presentation at the 58th Annual Meeting and Exposition of the American Society of Hematology, San Diego, USA, 3-6 December 2016. Presented on 3 December 2016. 3. Barr P, Robak T, Owen C, et al. Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia. Oral presentation at the 58th Annual Meeting and Exposition of the American Society of Hematology, San Diego, USA, 3-6 December 2016: Abstract #234. Disponible sur: https://ash.confex.com/ash/2016/webprogram/Paper89615.html. Dernière consultation novembre 2016. 5. Byrd J, Furman R, Coutre S, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32-42. 6. Johnson & Johnson. IMBRUVICA™ (ibrutinib) Now Approved in the U.S. for Patients with Chronic Lymphocytic Leukemia Who Have Received At Least One Prior Therapy. Press release, 12 February, 2014. Disponible sur: http://www.investor.jnj.com/releasedetail.cfm?releaseid=825570. Dernière consultation novembre 2016. 7. Burger J, Tedeschi A, Barr P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015:373:2435-37. 8. Janssen. Ibrutinib (IMBRUVICA®) Significantly Improved Progression-Free and Overall Survival Versus Chlorambucil in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia. Press release, 6 December 2015. Disponible sur: http://www.janssen.com/ibrutinib-imbruvica-significantly-improved-progression-free-and-overall-survival-versus-chlorambucil. Dernière consultation novembre 2016. 9. O’Brien S, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15:48-58.


News Article | November 2, 2016
Site: www.prnewswire.co.uk

AbbVie (NYSE: ABBV) today announced that it has mandated Barclays, BofA Merrill Lynch, Deutsche Bank, J.P. Morgan and Morgan Stanley (Global Coordinator) to organize a series of European fixed income investor meetings, commencing on Wednesday, November 9, 2016. An inaugural EUR-denominated senior unsecured multi-tranche benchmark transaction to refinance indebtedness will follow, subject to market conditions. AbbVie intends to use the proceeds of any offering together with existing cash on hand to repay all or a part of its 1.75% Senior Notes that mature on November 6, 2017. Relevant stabilization regulations including FCA/ICMA will apply. This announcement does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of such securities under the securities law of any such jurisdiction. This announcement is not being made, and this announcement has not been approved, by an authorized person for the purposes of section 21 of the United Kingdom Financial Services and Markets Act 2000, as amended (the "FSMA").‎ Accordingly, this announcement is not being distributed to, and must not be passed on to, the general public in the United Kingdom or to persons in the United Kingdom save in circumstances where section 21(1) of the FSMA does not apply. This announcement is made to and is directed only at persons in the United Kingdom having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) or are high net worth companies, unincorporated associations etc. falling within Article 49(2), in each case of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and to those persons to whom it can otherwise lawfully be distributed (all such persons together being referred to as "relevant persons"). This announcement and the securities referred to herein are, and will be made, available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, such relevant persons. No other person should rely or act upon it. This announcement is not intended for distribution to and must not be passed on to any retail client. The company has filed a shelf registration statement (including a prospectus) with the U.S. Securities and Exchange Commission (the "SEC"). Any offering of securities will be made only by means of a prospectus supplement, which will be filed with the SEC. In the event that the company proceeds with an offering, you may obtain a copy of the prospectus supplement and accompanying prospectus for the offering by visiting EDGAR on the SEC website at www.sec.gov, or from the company or the underwriters of that offering by contacting Barclays at 1-888-603-5847, BofA Merrill Lynch at 1-800-294-1322, Deutsche Bank at 1-800-503-4611, J.P. Morgan collect at +44-207-134-2468 and Morgan Stanley at 1-866-718-1649. AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view our Facebook and LinkedIn pages. This is a disclosure announcement from PR Newswire.


News Article | February 17, 2017
Site: www.prnewswire.co.uk

The board of directors of AbbVie Inc. (NYSE: ABBV) has authorized a $5 billion increase to AbbVie's existing stock repurchase program. Purchases may be made from time to time in management's discretion. The stock repurchase authorization permits shares to be repurchased in open market or private transactions, has no time limit and may be discontinued at any time. AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs approximately 30,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page. This is a disclosure announcement from PR Newswire.


Abexinostat tosylate of formula (II): and its crystalline form I characterised by its X-ray powder diffraction diagram, its Raman spectrum and its solid-state ^(13)C CP/MAS NMR spectrum. Medicinal products containing the same which are useful in the treatment of cancer.


News Article | February 27, 2017
Site: www.prnewswire.com

LONDON, Feb. 27, 2017 /PRNewswire/ -- This report provides all the information you require to better understand Pharmacyclics and its partnering interests and activities over the past five years.Download the full report: https://www.reportbuyer.com/product/3605648/DescriptionThe...

Loading Pharmacyclics collaborators
Loading Pharmacyclics collaborators